Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Diabetes

Free Subscription Articles published in Eur J Endocrinol Retrieve available abstracts of 56 articles: HTML format

Single Articles

March 2024
1. GETHER IM, Bahne E, Nerild HH, Rehfeld JF, et al
   Colesevelam has no acute effect on postprandial GLP-1 levels but abolishes gallbladder refilling.
   Eur J Endocrinol. 2024;190:314-326.
   PubMed     Abstract available
   
   
   
2. ATILA C, Beck J, Refardt J, Erlic Z, et al
   Psychopathological characteristics in patients with arginine vasopressin deficiency (central diabetes insipidus) and primary polydipsia compared to healthy controls.
   Eur J Endocrinol. 2024 Mar 29:lvae040. doi: 10.1093.
   PubMed     Abstract available
   
   
   
3. AHN HY, Lee J, Kang J, Lee EK, et al
   Increased risk of diabetes mellitus and hyperlipidemia in patients with differentiated thyroid cancer.
   Eur J Endocrinol. 2024;190:248-255.
   PubMed     Abstract available
   
   
   January 2024
4. MORGAN NG
   Insulitis in human type 1 diabetes: lessons from an enigmatic lesion.
   Eur J Endocrinol. 2024 Jan 17:lvae002. doi: 10.1093.
   PubMed     Abstract available
   
   
   December 2023
5. DAVIDSEN L, Jensen MH, Cook ME, Vestergaard P, et al
   Metformin Treatment is Associated with Reduced Risk of Hypoglycaemia, Major Adverse Cardiovascular Events, and All-Cause Mortality in Patients with Post-pancreatitis Diabetes Mellitus: A Nationwide Cohort Study.
   Eur J Endocrinol. 2023 Dec 22:lvad175. doi: 10.1093.
   PubMed     Abstract available
   
   
   
6. PERRIER M, Brugel M, Gerard L, Goichot B, et al
   Characteristics and treatment options of glucagonomas: a national study from the French Group of Endocrine Tumors and ENDOCAN-RENATEN network.
   Eur J Endocrinol. 2023;189:575-583.
   PubMed     Abstract available
   
   
   November 2023
7. CHUAN F, Gao Y, Liao K, Ye X, et al
   A simple fragility fracture risk score for type 2 diabetes patients: A derivation, validation, comparison, and risk-stratification study.
   Eur J Endocrinol. 2023 Nov 13:lvad150. doi: 10.1093.
   PubMed     Abstract available
   
   
   October 2023
8. GATTA-CHERIFI B, Laboye A, Gronnier C, Monsaingeon-Henry M, et al
   A novel pathogenic variant in MRAP2 in an obese patient with successful outcome of bariatric surgery.
   Eur J Endocrinol. 2023;189:K15-K18.
   PubMed     Abstract available
   
   
   September 2023
9. ORIOLI L, Canouil M, Sawadogo K, Ning L, et al
   Identification of myokines susceptible to improve glucose homeostasis after bariatric surgery.
   Eur J Endocrinol. 2023;189:409-421.
   PubMed     Abstract available
   
   
   August 2023
10. KIM J, Hong N, Choi J, Moon JH, et al
    Sex differences in mortality in patients with acromegaly: a nationwide cohort study in Korea.
    Eur J Endocrinol. 2023;189:225-234.
    PubMed     Abstract available
    
    
    
11. KENBORG L, Ebbehoj A, Ejerskov C, Handrup MM, et al
    Endocrine morbidity in neurofibromatosis 1: a nationwide, register-based cohort study.
    Eur J Endocrinol. 2023;189:190-198.
    PubMed     Abstract available
    
    
    July 2023
12. OLLILA MM, Arffman RK, Korhonen E, Morin-Papunen L, et al
    Women with PCOS have an increased risk for cardiovascular disease regardless of diagnostic criteria-a prospective population-based cohort study.
    Eur J Endocrinol. 2023;189:96-105.
    PubMed     Abstract available
    
    
    
13. FASSNACHT M, Tsagarakis S, Terzolo M, Tabarin A, et al
    European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors.
    Eur J Endocrinol. 2023;189:G1-G42.
    PubMed     Abstract available
    
    
    
14. LIN DS, Yu AL, Lo HY, Lien CW, et al
    Differential effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular and renal outcomes according to renal function: a dose-response meta-analysis involving 10 randomized clinical trials and 71 553 individuals.
    Eur J Endocrinol. 2023;189:S17-S25.
    PubMed     Abstract available
    
    
    
15. ROBLEDO KP, Marschner IC, Handelsman DJ, Bracken K, et al
    Mediation analysis of the testosterone treatment effect to prevent type 2 diabetes in the T4DM trial.
    Eur J Endocrinol. 2023 Jul 5:lvad074. doi: 10.1093.
    PubMed     Abstract available
    
    
    June 2023
16. OLSSON DS, Svensson M, Labori F, De Geer A, et al
    Healthcare cost and survival in patients with non-functioning pituitary adenoma.
    Eur J Endocrinol. 2023;188:477-484.
    PubMed     Abstract available
    
    
    
17. DOBBIE LJ, Cuthbertson DJ, Hydes TJ, Alam U, et al
    Mendelian randomisation reveals Sodium-glucose Cotransporter-1 inhibition's potential in reducing Non-Alcoholic Fatty Liver Disease risk.
    Eur J Endocrinol. 2023;188:K33-K37.
    PubMed     Abstract available
    
    
    May 2023
18. MINSCHART C, Myngheer N, Maes T, De Block C, et al
    Weight retention and glucose intolerance in early postpartum after gestational diabetes.
    Eur J Endocrinol. 2023 May 19:lvad053. doi: 10.1093.
    PubMed     Abstract available
    
    
    April 2023
19. AL-NASEEM AO, Attia A, Gonnah AR, Al-Naseem AOAS, et al
    Pancreas transplantation today: quo vadis?
    Eur J Endocrinol. 2023;188:R73-R87.
    PubMed     Abstract available
    
    
    February 2023
20. HONEGGER J, Giese S, Nasi-Kordhishti I, Donegan DM, et al
    Pregnancy-related hypophysitis revisited.
    Eur J Endocrinol. 2023;188:lvad003.
    PubMed     Abstract available
    
    
    
21. CHEONG HS, Chang Y, Kim Y, Joo EJ, et al
    Glycaemic status, insulin resistance, and risk of infection-related mortality: a cohort study.
    Eur J Endocrinol. 2023;188:lvad011.
    PubMed     Abstract available
    
    
    January 2023
22. CHO Y, Chang Y, Ryu S, Kim Y, et al
    Persistence or regression of prediabetes and coronary artery calcification among adults without diabetes.
    Eur J Endocrinol. 2023;188:lvac001.
    PubMed     Abstract available
    
    
    
23. YANG Y, Lin Q, Ma L, Lai Z, et al
    Maternal fasting glucose levels throughout the pregnancy and risk of adverse birth outcomes in newborns: a birth cohort study in Foshan city, Southern China.
    Eur J Endocrinol. 2023;188:lvac019.
    PubMed     Abstract available
    
    
    November 2022
24. ARIMA H, Cheetham T, Christ-Crain M, Cooper D, et al
    Changing the name of diabetes insipidus: a position statement of The Working Group for Renaming Diabetes Insipidus.
    Eur J Endocrinol. 2022;187:P1-P3.
    PubMed     Abstract available
    
    
    October 2022
25. NAHUM U, Refardt J, Chifu I, Fenske WK, et al
    Machine Learning Based Algorithm as an Innovative Approach for the Differentiation Between Diabetes Insipidus and Primary Polydipsia in Clinical Practice.
    Eur J Endocrinol. 2022 Oct 1. pii: EJE-22-0368. doi: 10.1530/EJE-22-0368.
    PubMed     Abstract available
    
    
    
26. ALEKSOVA J, Ebeling PR, Milat F, Elder GJ, et al
    DXA-derived advanced hip analysis and the trabecular bone score in end stage kidney disease secondary to type 1 diabetes.
    Eur J Endocrinol. 2022 Oct 1. pii: EJE-22-0687. doi: 10.1530/EJE-22-0687.
    PubMed     Abstract available
    
    
    
27. PEKKARINEN L, Kantonen T, Rebelos E, Latva-Rasku A, et al
    Obesity risk is associated with brain glucose uptake and insulin resistance.
    Eur J Endocrinol. 2022 Oct 1. pii: EJE-22-0509. doi: 10.1530/EJE-22-0509.
    PubMed     Abstract available
    
    
    September 2022
28. SPYROGLOU A, Handgriff L, Muller L, Schwarzlmuller P, et al
    The metabolic phenotype of patients with primary aldosteronism: impact of subtype and sex - a multicenter-study of 3566 Caucasian and Asian subjects.
    Eur J Endocrinol. 2022;187:361-372.
    PubMed     Abstract available
    
    
    
29. ALWAN H, Villoz F, Feller M, Dullaart RPF, et al
    Subclinical thyroid dysfunction and incident diabetes: a systematic review and an individual participant data analysis of prospective cohort studies.
    Eur J Endocrinol. 2022 Sep 1. pii: EJE-22-0523. doi: 10.1530/EJE-22-0523.
    PubMed     Abstract available
    
    
    August 2022
30. HAEDERSDAL S, Lund A, Nielsen-Hannerup E, Maagensen H, et al
    The Glucagon Receptor Antagonist LY2409021 does not affect gastrointestinal-mediated glucose disposal or the incretin effect in individuals with and without type 2 diabetes.
    Eur J Endocrinol. 2022 Aug 1. pii: EJE-22-0291. doi: 10.1530/EJE-22-0291.
    PubMed     Abstract available
    
    
    
31. MEYER NMT, Kabisch S, Dambeck U, Honsek C, et al
    Low IGF-1 and high IGFBP-1 predict diabetes onset in prediabetic patients.
    Eur J Endocrinol. 2022 Aug 1. pii: EJE-22-0034. doi: 10.1530/EJE-22-0034.
    PubMed     Abstract available
    
    
    
32. ROHDE C, Nielsen JS, Knudsen JS, Thomsen RW, et al
    Risk factors associated with mortality among individuals with type 2 diabetes and depression across two cohorts.
    Eur J Endocrinol. 2022 Aug 1. pii: EJE-22-0466. doi: 10.1530/EJE-22-0466.
    PubMed     Abstract available
    
    
    
33. TONG ZJ, Kuo CW, Yen PC, Lin CC, et al
    Acrolein plays a culprit role in the pathogenesis of diabetic nephropathy in vitro and in vivo.
    Eur J Endocrinol. 2022 Aug 1. pii: EJE-22-0493. doi: 10.1530/EJE-22-0493.
    PubMed     Abstract available
    
    
    July 2022
34. DILRUKSHI M, Vickars M, May C, Makaya T, et al
    Management of cranial Diabetes Insipidus - clinical outcomes and patient perception of care.
    Eur J Endocrinol. 2022 Jul 1. pii: EJE-22-0187. doi: 10.1530/EJE-22-0187.
    PubMed     Abstract available
    
    
    June 2022
35. STIDSEN JV, Christensen DH, Henriksen JE, Hojlund K, et al
    Risk of cardiovascular events associated with pathophysiological phenotypes of type 2 diabetes.
    Eur J Endocrinol. 2022 Jun 1. pii: EJE-22-0020. doi: 10.1530/EJE-22-0020.
    PubMed     Abstract available
    
    
    
36. YEAP BB, Marriott RJ, Manning L, Dwivedi G, et al
    Higher premorbid serum testosterone predicts COVID-19-related mortality risk in men.
    Eur J Endocrinol. 2022;187:159-170.
    PubMed     Abstract available
    
    
    
37. SKOV J, Kuja-Halkola R, Magnusson PKE, Gudbjornsdottir S, et al
    Shared etiology of type 1 diabetes and Hashimoto's thyroiditis: a population-based twin study.
    Eur J Endocrinol. 2022;186:677-685.
    PubMed     Abstract available
    
    
    May 2022
38. BLAGOJEVIC C, Heung T, Malecki S, Ying S, et al
    Hypertriglyceridemia in young adults with a 22q11.2 microdeletion.
    Eur J Endocrinol. 2022;187:91-99.
    PubMed     Abstract available
    
    
    
39. ATILA C, Gaisl O, Vogt DR, Werlen L, et al
    Glucagon-stimulated copeptin measurements in the differential diagnosis of diabetes insipidus: a double-blind randomized placebo-controlled study.
    Eur J Endocrinol. 2022 May 1. pii: EJE-22-0033. doi: 10.1530/EJE-22-0033.
    PubMed     Abstract available
    
    
    
40. SORGJERD EP, Mjelle R, Beisvag V, Flatberg A, et al
    Small RNAs are differentially expressed in autoimmune and non-autoimmune diabetes and controls.
    Eur J Endocrinol. 2022 May 1. pii: EJE-22-0083. doi: 10.1530/EJE-22-0083.
    PubMed     Abstract available
    
    
    April 2022
41. MCLENNAN NM, Hazlehurst J, Thangaratinam S, Reynolds RM, et al
    ENDOCRINOLOGY IN PREGNANCY: Targeting metabolic health promotion to optimise maternal and offspring health.
    Eur J Endocrinol. 2022;186:R113-R126.
    PubMed     Abstract available
    
    
    
42. MATHIESEN DS, Lund A, Holst JJ, Knop FK, et al
    THERAPY OF ENDOCRINE DISEASE: Amylin and calcitonin - physiology and pharmacology.
    Eur J Endocrinol. 2022;186:R93-R111.
    PubMed     Abstract available
    
    
    March 2022
43. BRONS C, Thuesen ACB, Elingaard-Larsen LO, Justesen L, et al
    Increased liver fat associates with severe metabolic perturbations in low birth weight men.
    Eur J Endocrinol. 2022;186:511-521.
    PubMed     Abstract available
    
    
    
44. ROHDE C, Finnerup NB, Schmitz N, Jensen TS, et al
    Is diabetic neuropathy associated with increased risk of developing mental disorders?
    Eur J Endocrinol. 2022 Mar 1. pii: EJE-21-1168. doi: 10.1530/EJE-21-1168.
    PubMed     Abstract available
    
    
    
45. BURGGRAAF B, Pouw NM, Fernandez Arroyo S, van Vark-van der Zee LC, et al
    Effects of dapagliflozin on postprandial lipid metabolism in type 2 diabetes mellitus.
    Eur J Endocrinol. 2022 Mar 1. pii: EJE-21-1270. doi: 10.1530/EJE-21-1270.
    PubMed     Abstract available
    
    
    February 2022
46. KOH HE, van Vliet S, Cao C, Patterson BW, et al
    Effect of obstructive sleep apnea on glucose metabolism.
    Eur J Endocrinol. 2022;186:457-467.
    PubMed     Abstract available
    
    
    
47. MCGLACKEN-BYRNE SM, Mohammad JK, Conlon N, Gubaeva D, et al
    Clinical and genetic heterogeneity of HNF4A/HNF1A mutations in a multicentre paediatric cohort with hyperinsulinaemic hypoglycaemia.
    Eur J Endocrinol. 2022;186:417-427.
    PubMed     Abstract available
    
    
    
48. GREEN CJ, Marjot T, Walsby-Tickle J, Charlton C, et al
    Metformin maintains intrahepatic triglyceride content through increased hepatic de novo lipogenesis.
    Eur J Endocrinol. 2022;186:367-377.
    PubMed     Abstract available
    
    
    
49. AJJAN RA, Hensor EMA, Del Galdo F, Shams K, et al
    Oral 11beta-HSD1 inhibitor AZD4017 improves wound healing and skin integrity in adults with type 2 diabetes mellitus: a pilot randomised controlled trial.
    Eur J Endocrinol. 2022 Feb 1. pii: EJE-21-1197.R1. doi: 10.1530/EJE-21-1197.
    PubMed     Abstract available
    
    
    
50. KUFE C, Micklesfield LK, Masemola M, Chikowore T, et al
    Increased Risk for Type 2 Diabetes in Relation to Adiposity in Middle-Aged Black South African Men compared to Women.
    Eur J Endocrinol. 2022 Feb 1. pii: EJE-21-0527. doi: 10.1530/EJE-21-0527.
    PubMed     Abstract available
    
    
    January 2022
51. HANDELSMAN DJ, Desai R, Conway AJ, Shankara-Narayana N, et al
    Recovery of male reproductive endocrine function after ceasing prolonged testosterone undecanoate injections.
    Eur J Endocrinol. 2022;186:307-318.
    PubMed     Abstract available
    
    
    December 2021
52. SONG Z, Gao M, Lv J, Yu C, et al
    Metabolically healthy obesity, transition to unhealthy phenotypes and type 2 diabetes in 0.5 million Chinese adults: The China Kadoorie Biobank.
    Eur J Endocrinol. 2021 Dec 1. pii: EJE-21-0743.R1. doi: 10.1530/EJE-21-0743.
    PubMed     Abstract available
    
    
    
53. HAEDERSDAL S, Lund A, Maagensen H, Nielsen-Hannerup E, et al
    The Glucagon Receptor Antagonist LY2409021 has No Effect on Postprandial Glucose in Type 2 Diabetes.
    Eur J Endocrinol. 2021 Dec 1. pii: EJE-21-0865.R1. doi: 10.1530/EJE-21-0865.
    PubMed     Abstract available
    
    
    November 2021
54. ZHANG J, Chen X, Liu W, Zhang C, et al
    Metabolic surgery improves the unbalanced proportion of peripheral blood myeloid dendritic cells and T lymphocytes in obese patients.
    Eur J Endocrinol. 2021;185:819-829.
    PubMed     Abstract available
    
    
    
55. ZHU M, Li Y, Dong G, Chen X, et al
    Prevalence and phenotypic features of diabetes due to recessive, non-syndromic WFS1 mutations.
    Eur J Endocrinol. 2021 Nov 1. pii: EJE-21-0097.R3. doi: 10.1530/EJE-21-0097.
    PubMed     Abstract available
    
    
    October 2021
56. HELMINK MAG, de Vries M, Visseren FLJ, de Ranitz WL, et al
    Insulin resistance and risk of vascular events, interventions and mortality in type 1 diabetes.
    Eur J Endocrinol. 2021 Oct 1. pii: EJE-21-0636.R1. doi: 10.1530/EJE-21-0636.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Diabetes is free of charge.